Breakthroughs in RNA editing and radioligand therapies are poised to take biotech into a new era – driving innovation, growth and new investment opportunities Biotechnology is entering a dynamic new ...

There’s a lot of froth in the stock market right now. Yet at the same time, there are also a lot of bargains for long-term investors. The post While there are bubbles in the stock market, this sector ...

Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment1Data will be shared with ...

Global equities advanced broadly in the third quarter, supported by a resilient US economy, expectations of continued ...

Enfortumab vedotin plus pembrolizumab improved EFS, OS, and pCR rates in MIBC patients ineligible for cisplatin-based chemotherapy. The combination therapy showed a median EFS and OS that were not ...

With the lupus treatment landscape poised for a shake-up, Roche is hitting t | Early Monday, Roche announced that the FDA ...

The U.S. Supreme Court declined on Monday to hear a bid by a group of physicians and healthcare providers to revive their ...

This model, combining technology, trusted partners, and personalized engagement, offers a blueprint for a prevention-first ...

The US Food and Drug Administration (FDA) has approved Tezspire (tezepelumab-ekko) for the add-on maintenance treatment of ...